Deltec Asset Management LLC has expanded its stake in Ocular Therapeutix by 2.9% during the second quarter. In total, the firm owns 2,794,892 shares after purchasing an additional 78,519 shares, reflecting the importance of the biopharmaceutical company in Deltec’s overall portfolio.
Deltec Asset Management LLC Boosts Holdings in Ocular Therapeutix, Inc. $OCUL

Key Takeaways:
- Deltec increased its position in Ocular Therapeutix by 2.9% during the second quarter
- The firm acquired 78,519 additional shares of the biopharmaceutical company
- Ocular Therapeutix now accounts for 4.6% of Deltec’s overall portfolio
- Deltec’s total holdings in Ocular Therapeutix stand at 2,794,892 shares
- The investment shift was reported by Holdings Channel and published in Markets Daily
Background of the Investment Move
Deltec Asset Management LLC has demonstrated increased confidence in Ocular Therapeutix, Inc. by boosting its holdings in the second quarter. The firm added 78,519 shares, marking a 2.9% jump in its overall stake. According to the Holdings Channel report, this move underscores Deltec’s strategic focus on the biopharmaceutical sector.
Significance for Deltec’s Portfolio
This latest addition now brings Deltec’s total holdings to 2,794,892 shares, making Ocular Therapeutix a notable part of the company’s investment mix. At 4.6% of the firm’s entire portfolio, the position indicates Ocular Therapeutix’s importance for Deltec’s long-term financial planning.
Ocular Therapeutix: A Biopharmaceutical Focus
Ocular Therapeutix specializes in developing and commercializing therapies targeting eye diseases. Although the news feed does not provide further product details, the company’s presence in the biopharmaceutical industry places it in a distinctive position for growth.
Looking Ahead
While neither Deltec nor Ocular Therapeutix has publicly shared any forward-looking statements in this particular update, the figures reported suggest a continued trust in the potential of Ocular Therapeutix. The additional shares and increased portfolio share underscore Deltec’s ongoing commitment to this partnership, making this a development worth watching in the biopharmaceutical investment landscape.
Table: Deltec’s Ocular Therapeutix Shares in Q2
Quarter | Position in Shares | Percentage Growth |
---|---|---|
2nd Quarter | 2,794,892 | 2.9% |
(Information sourced from Holdings Channel, as published by Markets Daily)